Abstract 465TiP
Background
Management of musculo-skeletal cancers patients has changed significantly with change in treatment paradigm from amputation to limb conservation. Limb Salvage Surgery (LSS) is now the standard of care. Moreover, increase in survival rates following advancement in the available multimodality treatment has lead to increased interest regarding the quality of life (QOL) and functional outcomes of the survivor patients. Unfortunately, all the QoL studies in published literature pertain to western population. This study aims to determine the functional outcomes and quality of life after performing limb salvage surgery in extremity sarcoma patients in Indian population in tertiary care hospital.
Trial design
Observational study Inclusion criteria- extremity sarcoma patients treated with either limb salvage surgery or amputation between the year Jan 2017 to Dec 2022. Extremities sarcomas includes bone tumors and soft tissue sarcomas between 14 and 50 years of age. Exclusion criteria-Non extremities sarcoma patients and patients with rotationplasty / turn-o-plasty procedures done Patients’ baseline socio-demographic and clinical characteristics (age, gender, morphology and the type of surgical intervention) as well as orthopedic or oncological complications occurring during the follow-up will be derived from the medical record. Questionnaires concerning QoL and functional outcomes which will be sent by post / telephonically or an interview with the investigators on outpatient basis. Assessment tools: Functional outcome will be measured using the Toronto extremity salvage score, Musculoskeletal tumor society score while Quality of life will be assessed using the EORTC QLQ-C30 QoL scale. Statistical Analysis: Descriptive analysis of quantitative parameters will be expressed as means and standard deviation. Categorical data will be expressed as absolute number and percentage. Independent Student's t-test will be used for testing of mean difference between independent groups. Cross tables will be generated and Chi square test will be used for testing of associations. P-value < 0.05 will be considered statistically significant. All analysis will be done using SPSS software, version 24.0.
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06